Corporate Profile Value through Innovation

Document Sample
Corporate Profile Value through Innovation Powered By Docstoc
					                                                                                                                                                                                                                   Corporate Profile

Nippon Boehringer Ingelheim Co., Ltd.
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku Tokyo 141-6017
   :
URL http://www.boehringer-ingelheim.co.jp




                                                                                                                                                                                Value t h ro ugh In n o vat io n




2010.06                                            Unauthorised use or reprint of text or images contained in this document is prohibited without obtaining prior permission.
                                                                                                                                                    COR P OR AT E PROF I L E




                                            We have committed ourselves
                                        to the goal of serving humankind
                                through development of innovative drugs .

                                                                 Nearing the summit.
                                       Taking composed and steady steps up the gently sloping hill.


                                     Being able to breathe deeply. Walking without shortness of breath.
                                Feeling enjoyment and happiness at being able to do my ordinary routine.


                          Focusing on patients’ needs and discovering new treatments, Boehringer Ingelheim
                           has committed itself to research into diseases and the development of innovative,
                                                             new drugs and therapies.


                                                   An innovative remedy from Boehringer Ingelheim contributes
                                               to the treatment of COPD (Chronic Obstructive Pulmonar y Disease).




    Va l u e t h ro u g h I n n ova t i o n
    “Value through Innovation” (VTI) is the vision of Boehringer Ingelheim and Lead & Learn outlines ways in which we realise and deliver VTI.
    It has helped us build on our strength, make the most of our distinctive character and achieve sustainable, organic growth for every employee
    and for Boeh ringer Ingelheim.




2                                                                                                                                                                              3
                                                                                                                                                                                                                                                                                                         COR P OR AT E PROF I L E



                                                                                                                                          Comments from the field where Lead & Learn is put into practice


    Lead & Learn
    Lead & Learn outlines in which we realise
    and deliver Value through Innovation
    Lead & Learn is about us, the people at Boehringer Ingelheim.
    It is about how we work together. It also serves as a guideline for employment, evaluation, education, and training
    and is the core of our corporate culture.



                                                                                                                                          All of our training courses enable employees to acquire        I truly think that the daily practice of Lead & Learn is                   I keep in mind to create a workplace in which team
                                                                                                                                          practical skills. CDPS training in particular made me          a shortcut to reaching my ideal of what I would like                       members can fully develop a personality for business
                                                                                                                                          realise that global strategies filtered down to all MRs        to become in the future. My current goal is to be a                        and strengthen their competitiveness. I would like
                                                                                                                                          once I had the chance to analyse our strategies from           positive influence on MRs around me. Through work                          to take the initiative to give constant support and
                                                                                                                                          the regional manager’s point of view. Working as an            and training, I came to realise my interest in people.                     guidance to each member so that they can realise
                                                                                                                                          MR at Boehringer Ingelheim is a rewarding job that             I am determined to improve my people skills and get                        their individual goals. Developing people also means
                                                                                                                                          allows self development and growth. I would like to            involved in any work that leads me to expand my own                        developing myself. I will strive to interact with as many
                                                                                                                                          accumulate a wide variety of experiences through               possibilities as well as those of the organisation.                        people as possible and continue to learn from them.
                                                                                                                                          polishing my sales skills and preparing myself to work         (Atsushi Takahashi, joined in 1999)                                        (Shoji Hanbe, District Manager, joined in 1991)
                                                                                                                                          on a global basis in the future.
                                                                                                                                          (Masaru Tsuyoshi, joined in 2002)




                                                                      Four Questions We Always Ask Ourselves                                       Human Resource Development Based on
                                                                                                                                                   Lead & Learn                                                                                  External Recognition of Human
                                                                      “Lead” in “Lead & Learn” means standing up for what we                                                                                                                     Resource Development
                                                                                                                                                   Boehringer Ingelheim is developing an environment to promote
                                                                      believe in and inspiring others to do the same. “Learn” means                                                                                                              Our workplace env ironment and human
                                                                                                                                                   a broad sense of knowledge and nurture the entrepreneurial                                    resource development systems based on
                                                                      looking to each other and to the market for knowledge and ideas
                                                                                                                                                   spirit for taking the initiative. Within this environment, free                               Lead & Learn have received a high level of
                                                                      to develop new and better ways.                                                                                                                                            appreciation from external institutions.
                                                                                                                                                   and open discussion is encouraged and employees build their
                                                                          In order to see if we are living up to these fundamentals, we                                                                                                          ● Selected as one of the best companies in a survey by
                                                                                                                                                   skills through training and work. Our vision builds a corporate                                  the Great Place to Work® Institute Japan (2010)
                                                                      ask ourselves the following four questions:
                                                                                                                                                                                                                                                 ●Awarded with “JMA HRD Excellence Award” by the
                                                                                                                                                   culture focused on continuous innovation in all areas and gives                                  Japan Management Association (2009)
                                                                                                                                                   employees direction.                                                                          ● Inducted into the Balanced Scorecard* Hall of Fame
                                                                                                                                                                                                                                                    for executing strategy as the first R&D based pharmaceutical
                                                                            Four questions we always ask Ourselves                                      Our employees are the “greatest eternal asset” in our                                       company (2007)
                                                                                                                                                   company. They are fully provided with opportunities to develop                                *Balanced Scorecard is a new management system in which strategies are
                                                                            ●Are we taking the initiative?                                                                                                                                        cascaded down and executed using a Strategy Map based on an organisation’s
                                                                                                                                                   themselves as professionals. This is exemplified by our training                               vision and mission. The progress of the strategies is managed and monitored
                                                                            ●Are we connected?                                                                                                                                                    by the Balanced Scorecard.
                                                                                                                                                   system, which includes introduction training to attain the
                                                                            ●Are we growing together?
                                                                                                                                                   business manner and professional skill to perform immediately
                                                                            ●Are we getting results?
                                                                                                                                                   after job assignment and the Career Step Programme that
                                                                                                                                                   improves abilities required at each position layer.
                                                                                                                                                        For those employees who proactively commit to challenges
                                                                      Lead & Learn will become our daily reality only when individual
                                                                                                                                                   and would like to think and act globally, many opportunities
                                                                      employees share results, experiences, and ideas and put them
                                                                                                                                                   sponsored by Boehringer Ingelheim are offered, such as CDPS
                                                                      into practice.
                                                                                                                                                   (Career Development Programme for Sales), an MR course for
                                                                                                                                                   creating next-generation leaders.




4                                                                                                                                                                                                                                                                                                                                        5
                                                                                                                                                                                                                                                                    COR P OR AT E PROF I L E


    Past, Present, and Future… 
    As a Successful Company
    that Continues to Grow
    Ever since its foundation in 1885, Boehringer Ingelheim has been built upon its continuous success as a pharmaceutical company.
    Boehringer Ingelheim has been widely acknowledged as a company trusted and relied upon by customers and as a company
    that globally operates its business based on its beliefs and distinctive character.
    Building on our experiences and achievements as a family-owned company, we intend to remain independent and are consistently
    oriented towards long-term, sustainable, organic growth.




                                                                                                                                      We Are a Globally Operating Pharmaceutical Company
                                                                                                                                      Dedicated to Research and Development

                                                                                                                                      Targeting Long-Term Sustainable Organic                            Serving Humankind through Research
                                                                                                                                      Growth as a Family-owned Company                                   into Diseases and Innovative Medicine
                                                                                                                                                                                                         Development
                                                                                                                                      Boehringer Ingelheim is a pharmaceutical company with a
                                                                                                                                      tradition dating back 125 years of history. It has grown into      Boehringer Ingelheim is committed to the goal of serving
                                                                                                                                      one of the top 20 global companies and has more than 40,000        humankind through research into diseases and the development
                                                                                                                                      employees in over 140 affiliated companies worldw ide.             of innovative drugs and therapies of human pharma and
                                                                                                                                      Boehringer Ingelheim is also recognised as a leading company       animal health. As a research-driven pharmaceutical company,
                                                                                                                                      in biopharmaceuticals.                                             Boehringer Ingelheim is engaged in worldwide drug discovery
                                                                                                                                          We maintain our position as a family-owned company             activ ities w ith its four main research facilities and two
                                                                                                                                      and have continuously grown, making sustainable, steady            supporting sites, including Japan.
                                                                                                                                      development.                                                           We have achieved stronger grow th than the global
                                                                                                                                          In Japan, Boehringer Ingelheim is engaged in the business      pharmaceutical market over the past decade and now possess
                                                                                                                                      operations of Prescription Medicine, Consumer Health Care,         a well-filled, highly promising pipeline.
                                                                                                                                      and Animal Health through its respective companies of Nipppon
                                                                                                                                      Boehringer Ingelheim, SSP, Boehringer Ingelheim Vetmedica Japan,
                                                                                                                                      and Boehringer Ingelheim Seiyaku as a manufacturing company.


                                                                                                                                                                                                                                     B I J E C ( B I J a p a n Exe cu t i ve Commi t te e )
                                                                                                                                                                                                                                     Members
                                                                                                                                                                                                                                     From the right:
                                                                                                                                                                                                                                     Dr. Thomas Heil
                                                                                                                                                                                                                                     Keisuke Otani
                                                                                                                                                                                                                                     Dr. Bruce Quinn
                                                                                                                                                                                                                                     Dr. Gerhard Koeller
                                                                                                                                                                                                                                     Dr. Yoshiki Nishikawa
                                                                                                                                                                                                                                     Toshio Tsuji
                                                                                                                                                                                                                                     Gerrard McKenna
                                                                                                                                                                                                                                     Dr. Thomas Kuerner
                                                                                                                                                                                                                                     Noriko Shiono
                                                                                                                                                                                                                                     Christoph Gauger




6                                                                                                                                                                                                                                                                                              7
                                                                                                                                                                                                                                                                                          COR P OR AT E PROF I L E




                                                                                                                                     Research & Development (R&D)


                                                                                                                                  Targeting Six Therapeutic Areas                                                         Our Drug Discovery Centres Located
                                                                                                                                                                                                                          Worldwide
                                                                                                                                  Through research and development, Boehringer Ingelheim
                                                                                                                                  constantly expands its pharmaceutical portfolio by bringing                             Boehringer Ingelheim is conducting clinical research in over
                                                                                                                                  into existence new drug candidates with true therapeutic                                50 countries and has four major R&D centres supported by
                                                                                                                                  benefits to patients. We are currently involved in six therapeutic                      two research sites, including Japan. Our global collaboration
                                                                                                                                  areas and we continue our drive for research and development                            ensures continuing improvement of R&D productivity and is our
                                                                                                                                  with the aim of establishing a position as a leading company in                         drive to deliver a prospective and well-balanced pipeline.
                                                                                                                                  important indication areas with high medical need.                                           As the Asian research arm, the Kobe Pharma Research
                                                                                                                                      In our constant quest for innovative drug discovery, we seek                        Institute assumes an important role in drug formulation and
                                                                                                                                  partnerships and alliances with external partners including                             development of the pipeline. This facility takes advantage of
                                                                                                                                  academic institutes, biopharmaceutical companies, and                                   remarkable drug formulation technologies and reflects market
                                                                                                                                  emerging corporations.                                                                  needs in Japan onto global drug development activities.




                                                                                                                                                                  Biberach (Germany)
                                                                                                                                                                    Vienna (Austria)                                    Laval (Canada)
                                                                                                                                                  Milan (Italy)                                                        Ridgefield (US)
                                                                                                                                                                                               Kobe (Japan)




                                                                                                                                                                                                                                                      Kobe Pharma Research Institute




                                                                                                                                    Biberach (Germany)                            Ridgefield (US)                         Kobe (Japan)                                 Milan (Italy)
                                                                                                                                    Field of research and development:            Field of research and development:      Support centre for molecular and             Support centre for chemical
                                                                                                                                    ●Neurological(CNS) diseases                   ● Cardiometabolic diseases              cellular biology and non-clinical drug       synthesis:
                                                                                                                                    ●Cardiometabolic diseases                     ●Immunology                             development:                                 ● Support for synthesis in
                                                                                                                                    ●Respiratory disease                          ● Non-clinical development              ● Support for international drug               exploratory and leading
                                                                                                                                    ●Non-clinical development                                                                discovery activities                        optimisation projects
                                                                                                                                                                                                                          ● Early drug formulation
                                                                                                                                    Vienna (Austria)                              Laval (Canada)                          ● Specific pharmacokinetic
                                                                                                                                    Field of research and development:            Field of research and development:         investigations
                                                                                                                                    ●Oncology                                     ● Infectious diseases




    Our Driving Force to Create New Value
    Research and development is the foundation of the success of our business and the driving force for the development of
    innovative new medicines for the treatment of diseases with an unmet therapeutic need. Out of a million screened molecules,
    only one has a chance to become available as a new drug.
    In the search for promising new drug candidates, every day our highly qualified researchers and developers work diligently,
    employing their talent as pioneers, advanced know-how of cutting-edge technology and their excellent communication skill.




8                                                                                                                                                                                                                                                                                                                    9
                                                                                                                                                                                                                                                       COR P OR AT E PROF I L E




                                                                                                                              Operations


                                                                                                                                                                                                GMP. We also maintain strict quality checks in all manufacturing
                                                                                                                           Boehringer Ingelheim Seiyaku
                                                                                                                                                                                                processes, including all active ingredients, materials, intermediate
                                                                                                                                                                                                products, packaging materials and finished products. Additionally,
                                                                                                                           The Boehringer Ingelheim Group conducts its operations at
                                                                                                                                                                                                physicochemical and microbiological monitoring is applied to
                                                                                                                           cutting-edge manufacturing facilities around the world served
                                                                                                                                                                                                the water and all areas used for manufacturing.
                                                                                                                           by highly experienced and knowledgeable personnel.
                                                                                                                                                                                                    The Quality Control group is always looking for improvement
                                                                                                                               Boehringer Ingelheim Seiyaku assumes an important role
                                                                                                                                                                                                opportunities and performs complete quality checks for all
                                                                                                                           as a strategic factory and production site in Japan and ensures
                                                                                                                                                                                                ingredients, packaging materials, bulks, and finished products
                                                                                                                           global standard pharmaceuticals through superior drug
                                                                                                                                                                                                based on in-house standards. In addition, stability tests, quality
                                                                                                                           formulation technologies and advanced facilities with thorough
                                                                                                                                                                                                confirmation, and validation tests of each product and other
                                                                                                                           quality control.
                                                                                                                                                                                                various tests, such as investigations for complaint handling and
                                                                                                                           Excellent Human Resources is the Most                                compatibility are also conducted. In compliance with relevant
                                                                                                                           Critical Success Factor                                              laws and regulations, the Quality Assurance group confirms the
                                                                                                                                                                                                status of manufacturing and quality controls and determines
                                                                                                                           One of our most important success factors is our people. They
                                                                                                                                                                                                the product release. By establishing this sophisticated quality
                                                                                                                           have the right business process excellence mindset to do their
                                                                                                                                                                                                management system, we incorporate all possible means to
                                                                                                                           utmost to deliver the right product at the right time. Putting
                                                                                                                                                                                                assure the quality of the products manufactured at the plant.
                                                                                                                           Lead & Learn into practice every day, they always take initiative,
                                                                                                                           lead others, and create new and better ways through learning.
                                                                                                                               Boehringer Ingelheim Seiyaku sponsors a wide range of specific
                                                                                                                           training courses, including GMP (Good Manufacturing Practice)
                                                                                                                           training and EHS (Environmental, Health and Safety) training.

                                                                                                                           Maintaining and Improving Perfect
                                                                                                                           Quality Control
                                                                                                                           Along with maintaining an integrated production system from
                                                                                                                           drug formulation to packaging and warehouse management,
                                                                                                                           we have established a quality control system in accordance with           Boehringer Ingelheim Seiyaku (Higashine City, Yamagata Prefecture)




     Human Resources and State-of-the-Art
     Facilities Create Optimum Production Quality
     Boehringer Ingelheim has a word-class pharmaceutical production network.
     In Japan, the company is armed w ith sophisticated drug formulation technologies and state-of-the-art manufacturing
     facilities operated by highly experienced personnel.
     It is our mission to bring forward continuous innovation and pursue quality and compliance at the highest level.
     All efforts go to providing products and services that exceed the expectations of our customers.




10                                                                                                                                                                                                                                                                            11
                                                                                                                                                                                                                                                                                          COR P OR AT E PROF I L E




                                                                                                                                                                Medical Representative (MR)


                                                                                                                                                                                                                                                             Team Activities
                                                                                                                                                             As a Best Partner for Medical                                                                      Reporting,
                                                                                                                                                                                                                                                            communicating, and
                                                                                                                                                             Practitioners                                                                                   consulting on daily
                                                                                                                                                                                                                                                                 activities


                                                                                                                                                             On behalf of the company, MRs collect evaluations and
                                                                                                                                                                                                                                                         Collecting evaluations
                                                                                                                                                             feedback from physicians, pharmacists and other medical                                         and feedback of
                                                                                                                                                                                                                                 Understanding                                           Self-study
                                                                                                                                                             practitioners in order to promote proper use of drugs, and they       Strategies               the medicines and           Full use of the
                                                                                                                                                                                                                                                                                       product medical
                                                                                                                                                                                                                                   Participation in     distributing information         information
                                                                                                                                                             also distribute precise information on the efficacy and safety of   field force strategy
                                                                                                                                                                                                                                      meetings          to promote proper use of           database

                                                                                                                                                             their company’s products.                                                                          the drugs

                                                                                                                                                                 The diverse activities of MRs are comprised of conducting
                                                                                                                                                                                                                                                             Cross-function
                                                                                                                                                             product presentations for physicians and pharmacists,                                           Communication
                                                                                                                                                                                                                                                          With other departments
                                                                                                                                                             responding to inquiries from medical practitioners, preparing                                Supporting clinical trials
                                                                                                                                                                                                                                                             and conducting
                                                                                                                                                                                                                                                             Post-Marketing
                                                                                                                                                             clinical references, and visiting pharmaceutical wholesalers.                                     Surveillance



                                                                                                                                                             MRs Develop Themselves through
                                                                                                                                                             Relationships with Customers                                            Qualities required for MR
                                                                                                                                                                                                                                     Each MR is expected to attain a high level of academic
                                                                                                                                                             In order to achieve their own cont inuous grow th and
                                                                                                                                                                                                                                     knowledge and ethics. MR activ ities are ver y much
                                                                                                                                                             development as well as that of the company, Boehringer                  at the discretion of the indiv idual and thus require
                                                                                                                                                             Ingelheim MRs act in a spirit of entrepreneurship to lead others        aspiration and strong self-discipline.
                                                                                                                                                                                                                                            Boehringer Ingelheim’s MRs are expected to put
                                                                                                                                                             and find new ideas through their daily work. A wide range of
                                                                                                                                                                                                                                     Value through Innovation into practice. In other words,
                                                                                                                                                             in depth knowledge and sophisticated communication skill                being an MR requires integrity to live up to promises
                                                                                                                                                             cultivated through internal relationships and externally with           and fulfil responsibilities, tenacious action to respond
                                                                                                                                                                                                                                     to the needs of customers and achieve goals, high
                                                                                                                                                             medical practitioners enable them to do their best and take
                                                                                               In addition to committing myself as an MR to deliver                                                                                  level communication skill to bring results as a team,
                                                                                               medical information, I am also engaged in activities in       on higher challenges. MRs take pride and fulfilment in being
                                                                                                                                                                                                                                     flexibilit y to adapt to new env ironment, and strong
                                                                                               the local community, participating in the figure skating
                                                                                                                                                             part of medical care and contributing to human health through           motivation to voluntarily address challenges.
                                                                                               competition of the National Athletic Meet as a female
                                                                                               single skater representing Nagano Prefecture. Common          exceeding expectations in every activity.
                                                                                               to both activities is the fact that daily efforts lead to
                                                                                               great results. I’d like to continue to surpass expectations
                                                                                               in both my work and my personal goals and activities.
                                                                                               (Kaori Takeda, joined in 2008)




     Building Trust through Activities
     that Exceed Expectations
     Representing Boehringer Ingelheim, MRs prov ide pharmaceutical information at the frontline to the field of medical
     treatment. MRs take independent responsibilities based on their own judgment, look into the future with confidence, and are
     unyielding in achieving their targets. They take great pride in Boehringer Ingelheim’s products and are always aware of the
     joy and responsibility of contributing to patients’ health and well-being.




12                                                                                                                                                                                                                                                                                                              13
                                                                                                                                                                                                                                                                        COR P OR AT E PROF I L E




     Business Areas
     Focusing on Developing Innovative Medicines
     Our business consists of Prescription Medicines, Consumer Health Care, Animal Health, and Pharma Chemicals.
     We take pride and joy in responding to various customer needs and contributing to humankind with our excellence in medical,
     marketing and production expertise.




                                                                     Our Business                                                           Prescription Medicines
                                                                                                                                           Nippon Boehringer Ingelheim
                                                                     Focusing on innovative drugs and treatments that represent major
                                                                     therapeutic advances, Boehringer Ingelheim has established its
                                                                     position as a global brand in various business and therapeutic
                                                                                                                                         Growing with Innovative Prescription Medicines Focusing on the Needs of Patients
                                                                     areas. We have secured a leading position in biopharmaceuticals
                                                                     with our excellence in innovation and technology.                   Boehringer Ingelheim’s innovative medicines have been                          overseas. Such trials include ONTARGET® to study the efficacy
                                                                         Our prescription medicine business has established a firm       reaching patients around the world. Products with highly                       of the long-term administration of telmisartan (Micardis®),
                                                                     global position and is continuing to grow steadily. In addition,    reliable evidence, such as Micardis® for the treatment of                      UPLIFT® for tiotropium (Spiriva®), and RE-LY® to study the safety
                                                                     we possess a prospective pipeline that will lead us to further      essential hypertension, Spiriva® for the treatment of COPD, and                and efficacy of Dabigatran (oral anticoagulant). Furthermore, we
                                                                     future success.                                                     Bi-Sifrol® for the treatment of Parkinson’s disease and restless               have a prospective pipeline that allows us to lead to continuous,
                                                                         In Japan, SSP is responsible for the Consumer Health Care       legs Syndrome (RLS), are distributed in the Japanese market                    organic growth.
                                                                     segment and focuses mainly on over-the-counter (OTC) medicines.     which is one of the most important markets.                                         Our steady investment in R&D is substantial and it
                                                                         In the field of Animal Health, we provide innovative vaccines       We continue to evaluate the efficacy and safety of existing                corresponds to one-fifth of net sales. Clinical trials of innovative
                                                                     and treatments driven by our global R&D power to contribute to      products and conduct clinical trials involving tens of thousands               compounds from our own research are in progress in Japan,
                                                                     the health and happiness of animals and people.                     of patients globally. Large-scale clinical trials have gained a                including Dabigatran, DPP-IV inhibitor for type 2 diabetes, and
                                                                         Pharma Chemicals is accountable for import, marketing,          high level of evaluation from medical professionals in Japan and               a number of oncology compounds.
                                                                     and sales of active pharmaceutical ingredients and inter-
                                                                     mediates, as well as promotion of custom production for
                                                                     Japanese industrial customers. In addition, our operation
                                                                     division manufactures our company products using our global
                                                                     production network, and assumes an important and strategic
                                                                                                                                             Serving Humankind with Innovative Medicines
                                                                     role as a production site in Japan.
                                                                                                                                             Chronic Obstructive Pulmonary Disease (COPD) is the lifestyle-attributed lung disease chiefly caused by
                                                                         Partnering is an integral part of the company’s business
                                                                                                                                             cigarette smoking. It is estimated that more than five million Japanese people over forty years of age suffer
                                                                     strategy. The Head Office, as the centre of operations, seeks           from COPD. Spiriva@ has a positive impact on the clinical course of COPD, helping to change the way patients
                                                                     global licensing agreement opportunities with innovative                live with their disease.
                                                                     partners around the world.




14                                                                                                                                                                                                                                                                                             15
                                                                                                                                                                                                                                                                                                 COR P OR AT E PROF I L E




        C onsumer He alth C are                                                                       A nimal He alth                                                                                   Pharma Chemic als
                                                                                                      Boehringer Ingelheim Vetmedica             Japan                                                  Nippon Boehringer Ingelheim


     Bringing Groundbreaking OTC Drugs                                                             Leading Provider of Innovative                Vaccines                                            Pursuing Customer Satisfaction with Over a Century
     for the Improvement of Health                                                                 and Therapies for Animals                                                                         of Expertise and Experience
     While both the government and the private      general fatigue remedy, and “Surulac”          For more than 50 years, the Animal Health        and respiratory syndrome (PRRS), and             As the Japanese representative, Pharma                                Throughout its more than 100 years of
     sector promote self-medication in which        constipation reliever. These trusted brands    business has been providing solutions for        Ingelvac® M.hyo, a single shot mycoplasma        Chemicals is responsible for marketing,                       history, customer satisfaction has been the
     consumers manage their own health and          are gaining trust and popularity amongst       the prevention and treatment of diseases         hyopneumoniae vaccine. We also specialise        import sales, and outsourced production                       central focus of Boehringer Ingelheim. By
     prevent disease, the consumer health care      the people of Japan.                           in animals. Its business has developed           in the cattle and poultry businesses.            op er at ions of me d ic ine and me dic al                    having state-of-the-art research facilities,
     market in Japan is expected to develop and         Placing first priority on the health and   in more than 60 countries and has been                In the field of companion animals,          intermediates manufac tured at the                            extremely flexible and versatile production
     further mature in the future.                  happiness of customers and improving           one of the fastest-growing international         we address solutions to create longer and        B o ehr inger Inge lhe im Gr oup’s c GMP                      equipment, and strict quality standards, we
         In Japan, SSP Co., Ltd which joined        their quality of life, SSP continues to        companies, becoming one of the top 10            healthier lives for our four-legged friends.     compliant factories in Germany, Italy, Spain,                 are capable of responding to a wide range
     BI Japan group of companies in 2001 is         carry out boundless research and forge         companies in the animal health industry.         Ever since its launch in February 2008,          and the US. Boehringer Ingelheim is a leading                 of customer needs from research-led start-
     in charge of the consumer health care          new challenges. Through the Boehringer         Boehringer Ingelheim Vetmedica Japan             Vetmedin®, a break through treatment             company that manufactures high quality                        ups to the major pharmaceutical groups.
     business.                                      Ingelheim Group global network, the            (B I V J) is c onduc t ing animal he al t h      for congestive heart failure in dogs, has        pharmaceutical ingredients that comply with                           Taking full advantage of our global
         Ever since its foundation in 1765, SSP     company secures the newest seeds and           operations in Japan.                             become the market leader in medicines            or exceed pharmacopeias worldwide.                            logistics and sales network as well as our
     has contributed to improving national          information in order to strengthen its             In the f ield of livestock farming,          for circulatory systems of dogs and our               We manufacture and supply innovative                     expertise in regulations and technologies,
     health as one of the leading Japanese          proprietary technology.                        we concentrate on the improvement of             main product at present. This is in addition     products in the fields of phytochemical (a                    our Pharma Chemicals customers trust
     pharmaceutical companies.                          Under the SSP philosophy of becoming       productivity and profitability of farms.         to Metacam®, our non-steroidal anti-             chemical substance obtained by isolating                      Boehringer Ingelheim as a highly
         With its excellent capability to develop   a reliable and friendly guarantor of health    Our innovative information and support           inflammatory drug, and Viacutan® Plus,           and refining plant-derived components),                       competent partner to deliver the precise
     innovative products and technologies for       care, SSP has committed itself to being        services have led us to become the market        feed supplement which contains GL A              organic chemical synthesis, and medical                       support they require globally to ensure
     drug formulation, SSP has created a wide       a “cus tome r- or ie nte d” bus ine s s by     leader of swine vaccines since 2008. In          essential fatty acid supplement with natural     biodegradable polymers.                                       value creation.
     range of products tailored to the needs        providing pharmaceuticals that support         March 2008, we launched in Japan the             antioxidants for dogs and cats. The sound                                                Drug Development Process
     of various life styles and stages. Major       an ideal lifestyle for all individuals.        first preventive vaccine against diseases        expertise in scientific research at Boehringer
                                                                                                                                                                                                                Exploration                                                       Approval and
                                                                                                                                                                                                                                        New              Clinical trials                               Product
     brands include “Eve” analgesic/antipyretic                                                    associated w ith porcine circov irus 2           ingelheim allows BIVJ to deliver a wide                     of chemical
                                                                                                                                                                                                                                     compounds           (PhaseⅠ-Ⅲ)
                                                                                                                                                                                                                                                                                  planning for         launch
                                                                                                                                                                                                                compounds                                                            launch
     and “S. Tac” general cold remedy, “S.                                                         callled Ingelvac® CircoFLEX. Our other           range of innovating products to the benefit
                                                                                                                                                                                                           Compound development                       Process development                   Manufacturing
     Cup” energy drink, “Hythiol-C” chloasma/                                                      main products are the patented Ingelvac®,        of both animals, and ultimately, humans.
                                                                                                                                                                                                     Boehringer Ingelheim Pharma Chemicals provides innovative solutions for industrial customers.
                                                                                                   PRRS vaccine for porcine reproductive



16                                                                                                                                                                                                                                                                                                                      17
                                                                                                                                                      COR P OR AT E PROF I L E




                                                                                                                                                                                   Are we ...
     Corporate Responsibility
     Living Our Values
     Our Caring Culture
     of Responsibility and
     Commitment

     Corporate Responsibility has been an integral part of our corporate culture for more than 100 years. We seek to foster economic and
     social well-being in the countries and communities where we do business. Our activities therefore emanate from our operating units
     in each country and embrace patients and neighbouring communities in society at large.
     We strive to fulfil our mission to serve humankind through a broad range of social activities reflecting our strengths as a
     pharmaceutical company.




     Viramune® Donation Programme                                                                      its mission of development of basic science as one of its social

     Commitment to Combating Mother-to-                                                                contributions. We believe that scientists who build a bridge to

     Child Transmission of AIDS                                                                        basic research and science can support the development of
                                                                                                       R&D in the pharmaceutical industry. We encourage excellent
     B o ehr inger Inge lhe im share s t he v ie w t hat ac c e s s to                                 activities of researchers who turn their curiosity into science,
     medicines saving human lives should not be limited to those                                       recognising these efforts through the “Baelz Award” and the “BI
     who can afford them. Based on this policy, we have been                                           Pharmacist Award” in Japan.
     donating our non nucleoside reverse transcriptase inhibitor
                                                                                                       Environment, Health, and Safety (EHS)
     Viramune®*(nevirapine) to target the prevention of mother-to-
     child transmission of the HIV-1 virus in countries most in need.                                  As written in the stated core principles "Leitbild" of Boehringer
     In addition to the Viramune® Donation Programme, Boehringer                                       Ingelheim, the health and safety of our employees and the
     Ingelheim with four major pharmaceutical companies and five                                       protection of the environment has a very high priority, a fact also
     UN organisations have allied to supply drugs to developing
     countries at prices lower than those of developed countries.
                                                                                                       underlined by our principles on Environmental Health & Safety
                                                                                                       (EHS). Based on these principles, we are focusing on reducing
                                                                                                                                                                                 taking the initiative?
     *A non-nucleoside reverse transcriptase inhibitor, a product of original research at Boehringer
      Ingelheim. In Japan, it is not permitted to use Viramune® to prevent maternal infection.
                                                                                                       energy consumption and CO2 emissions by introducing energy
                                                                                                       efficient equipment, environmental emissions control, and
                                                                                                                                                                                 connected?
                                                                                                                                                                                 growing together?
                                                                                                       improvement of recycling rates. The quality and achievement of
     Supporting Researchers to Turn Curiosity
                                                                                                       these programmes are regularly checked through internal and
     into Science
                                                                                                       external audits.
     As an R&D-driven company, Boehringer Ingelheim addresses                                                                                                                    getting results?
                                       For further details of our Caring Culture activities, please visit the Boehringer Ingelheim Japan website at
                                             (http://www.boehringer-ingelheim.co.jp/com/Home/Corporate/Our_We_Care_Principals/)


                                                                                                                                                                                   Lead & Learn           ABCD
18

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:42
posted:8/12/2011
language:English
pages:10